Novel clinical and radiomic predictors of rapid disease progression phenotypes among lung cancer patients treated with immunotherapy: An early report
Open accessThe DOI matches its Crossref record; 11 of the 11 references it cites were found in a registry or an index.
Abstract
Objectives Immune-checkpoint blockades have exhibited durable responses and improved long-term survival in a subset of advanced non-small-cell lung cancer (NSCLC) patients. However, highly predictive markers of positive and negative responses to immunotherapy are a significant unmet clinical need. The objective of this study was to identify clinical and computational image-based predictors of rapid disease progression phenotypes in NSCLC patients treated with immune-checkpoint blockades. Materials and Methods Using time-to-progression (TTP) and/or tumor growth rates, rapid disease progression phenotypes were developed including hyperprogressive disease. The pre-treatment baseline predictors that were used to identify these phenotypes included patient demographics, clinical data, driver mutations, hematology data, and computational image-based features (radiomics) that were extracted from pre-treatment computed tomography scans. Synthetic Minority Oversampling Technique (SMOTE) was used to subsample minority groups to eliminate classification bias. Patient-level probabilities were calculated from final clinical-radiomic models to subgroup patients by progression-free survival (PFS). Results Among 228 NSCLC patients treated with single agent or double agent immunotherapy, we identified parsimonious clinical-radiomic models with modest to high ability to predict progression phenotypes with area under the receiver-operator characteristics ranging from 0.812 to 0.843. Patients who experienced TTP < 2 months or hyperprogressive disease were classified with 73.4% and 82.3% accuracy after SMOTE subsampling, respectively. When the patient subgroups based on patient-level probabilities were analyzed for survival outcomes, patients with higher probability scores had significantly worse PFS. Conclusions The models found in this study have potential important translational implications to identify highly vulnerable NSCLC patients treated with immunotherapy that experience rapid disease progression and survival poor outcomes.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer
Reck, M., Rodríguez-Abreu, D., Robinson, A. G., Hui, R., Csőszi, T., Fülöp, A., Gottfried, M., Peled, N., Tafreshi, A., Cuffe, S., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1606774 · Cited by 10,089
Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer
Borghaei, H., Paz-Ares, L., Horn, L., Spigel, D. R., Steins, M., Ready, N. E., Chow, L. Q., Vokes, E. E., Felip, E., Holgado, E., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1507643 · Cited by 9,335
Nivolumab versus Docetaxel in Advanced Squamous-Cell Non–Small-Cell Lung Cancer
Brahmer, J., Reckamp, K. L., Baas, P., Crinò, L., Eberhardt, W. E. E., Poddubskaya, E., Antonia, S., Pluzanski, A., Vokes, E. E., Holgado, E., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1504627 · Cited by 8,447
Radiomics: Images Are More than Pictures, They Are Data
Gillies, R. J., Kinahan, P. E., & Hricak, H. (2016) · Radiology · doi:10.1148/radiol.2015151169 · Cited by 8,421
Self-citationPembrolizumab plus chemotherapy in metastatic non–small-cell lung cancer
Gandhi, L., Rodríguez-Abreu, D., Gadgeel, S., Esteban, E., Felip, E., De Angelis, F., Domine, M., Clingan, P., Hochmair, M. J., Powell, S. F., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1801005 · Cited by 6,607
Self-citationHerbst, R. S., Baas, P., Kim, D.-W., Felip, E., Pérez-Gracia, J. L., Han, J.-Y., Molina, J., Kim, J.-H., Arvis, C. D., Ahn, M.-J., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(15)01281-7 · Cited by 6,449
Elements of cancer immunity and the cancer–immune set point
Chen, D. S., & Mellman, I. (2017) · Nature · doi:10.1038/nature21349 · Cited by 5,352 · cited 1×
“However, overall response rates are only about 20 to 50% and those that do not respond can experience accelerated and lethal progression described as hyperprogressive disease (HPD) [7, 8].”
BackgroundDecoding tumour phenotype by noninvasive imaging using a quantitative radiomics approach
Aerts, H. J. W. L., Velazquez, E. R., Leijenaar, R. T. H., Parmar, C., Grossmann, P., Carvalho, S., Bussink, J., Monshouwer, R., Haibe-Kains, B., Rietveld, D., et al. (2014) · Nature Communications · doi:10.1038/ncomms5006 · Cited by 5,132 · cited 1×
“As radiomic features have been shown to capture biological information and genomic pathways [12] and correlate with genomic mutations [26], we speculate that these features associated with rapid disease progression could be capturing one or more of these characteristics.”
BackgroundSelf-citationThe tumor microenvironment and its role in promoting tumor growth
Whiteside, T. L. (2008) · Oncogene · doi:10.1038/onc.2008.271 · Cited by 2,376 · cited 1×
“Increased NLR is a measure of reduced lymphocytes which suppresses the host immune response where elevated NLR in the blood could be an implication of inflammatory cells being present in tumor microenvironment (TME) that leads to immune evasion or escape from the immune intervention [21].”
BackgroundPD-L1 expression as a predictive biomarker in cancer immunotherapy
Patel, S. P., & Kurzrock, R. (2015) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-14-0983 · Cited by 2,291 · cited 1×
“Though PDL1 immunohistochemistry (IHC) is a widely applied biomarker to select patients for immunotherapy, PD-L1 expression alone is not adequate to predict response [9, 10].”
BackgroundMezquita, L., Auclin, E., Ferrara, R., Charrier, M., Remon, J., Planchard, D., Ponce, S., Ares, L. P., Leroy, L., Audigier-Valette, C., et al. (2018) · JAMA Oncology · doi:10.1001/jamaoncol.2017.4771 · Cited by 913
Cited by
Predicting cancer outcomes with radiomics and artificial intelligence in radiology
Bera, K., Braman, N., Gupta, A., Velcheti, V., & Madabhushi, A. (2022) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-021-00560-7 · Cited by 819
Artificial Intelligence for Predictive Biomarker Discovery in Immuno-Oncology: A Systematic Review
Prelaj, A., Miskovic, V., Zanitti, M., Trovo, F., Genova, C., Viscardi, G., Rebuzzi, S. E., Mazzeo, L., Provenzano, L., Kosta, S., et al. (2024) · Annals of Oncology · doi:10.1016/j.annonc.2023.10.125 · Cited by 340
Defining clinically useful biomarkers of immune checkpoint inhibitors in solid tumours
Holder, A. M., Dedeilia, A., Sierra-Davidson, K., Cohen, S., Liu, D., Parikh, A., & Boland, G. M. (2024) · Nature Reviews Cancer · doi:10.1038/s41568-024-00705-7 · Cited by 298
Sun, R., Sundahl, N., Hecht, M., Putz, F., Lancia, A., Rouyar, A., Milic, M., Carré, A., Battistella, E., Alvarez Andres, E., et al. (2020) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2020-001429 · Cited by 94
Polk, S. L., Choi, J. W., McGettigan, M. J., Rose, T., Ahmed, A., Kim, J., Jiang, K., Balagurunathan, Y., Qi, J., Farah, P. T., et al. (2020) · World Journal of Gastroenterology · doi:10.3748/wjg.v26.i24.3458 · Cited by 48
Self-citation
Metadata
- Authors
- Tunali, I., Gray, J. E., Qi, J., Abdalah, M., Jeong, D. K., Guvenis, A., Gillies, R. J., & Schabath, M. B.
- Venue
- Lung Cancer
- Publisher
- Elsevier BV
- Published
- 2019-03
- Volume
- 129
- Pages
- 75-79
- ISSN
- 0169-5002 (ISSN-L)
- OpenAlex
- W2914472860
- Cited by
- 144
- References
- 11
- FWCI
- 13.65
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.